Asia Deal Watch: BIOCAD, Shanghai Pharma Agree On Pair Of Russian/Chinese Joint Ventures
Executive Summary
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.
You may also be interested in...
Another Infliximab Biosimilar On Horizon In India?
More competition appears to be in the wings for Remicade in India after the Russian firm Biocad’s biosimilar infliximab was endorsed in India by an expert panel, though there’s little clarity on launch specifics, at least for now.
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Rohto’s Cirrhosis Cell Therapy Finds Japan Partner In Shionogi
In a sign of continued corporate interest in the regenerative and cell therapy area in Japan, Shionogi has acquired rights in this market to a novel cirrhosis treatment being developed by Rohto.